Related references
Note: Only part of the references are listed.Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
Ivan Alic et al.
MOLECULAR PSYCHIATRY (2021)
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2
Kazuki Fujimoto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of Extremely Selective Fused Pyridine-Derived β-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions
Tatsuhiko Ueno et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2
Liping H. Pettus et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Questions EMERGE as Biogen claims aducanumab turnaround
Robert Howard et al.
NATURE REVIEWS NEUROLOGY (2020)
3,3-Difluoro-3,4,5,6-tetrahydropyridin-2-amines: Potent and permeable BACE-1 inhibitors
Aldo Peschiulli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
Gerald Novak et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2
Kazuki Fujimoto et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
New evolutions in the BACE1 inhibitor field from 2014 to 2018
Chien-Chi Hsiao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
Kaichuan Zhu et al.
BIOLOGICAL PSYCHIATRY (2018)
Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5
Matteo Rossi Sebastiano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation
Brian T. O'Neill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization
Kenji Nakahara et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate
Harrie J. M. Gijsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Development of a Human iPSC Cardiomyocyte-Based Scoring System for Cardiac Hazard Identification in Early Drug Safety De-risking
Ivan Kopljar et al.
STEM CELL REPORTS (2018)
Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons
Martina Pigoni et al.
MOLECULAR NEURODEGENERATION (2016)
Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice
Derya R. Shimshek et al.
SCIENTIFIC REPORTS (2016)
How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model
Guizhi Liu et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2016)
hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia
Hisashi Nogawa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Comparison of Two Different Methods for Measurement of Amyloid-β Peptides in Cerebrospinal Fluid after BACE1 Inhibition in a Dog Model
Herman Borghys et al.
JOURNAL OF ALZHEIMERS DISEASE (2014)
An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex
Ye Zhang et al.
JOURNAL OF NEUROSCIENCE (2014)
EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides
Gilles H. Goetz et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease
Hans Hilpert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells
Leila Rochin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Clifford R. Jack et al.
ARCHIVES OF NEUROLOGY (2012)
In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs
Richard A. Thompson et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Conformational Restriction Approach to β-Secretase (BACE1) Inhibitors: Effect of a Cyclopropane Ring To Induce an Alternative Binding Mode
Shuji Yonezawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline
Thorlakur Jonsson et al.
NATURE (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease
B. Van Broeck et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and Mass
Daria Esterhazy et al.
CELL METABOLISM (2011)
Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β′-site increases Aβ generation
Lujia Zhou et al.
EMBO MOLECULAR MEDICINE (2011)
Di-substituted pyridinyl aminohydantoins as potent and highly selective human β-secretase (BACE1) inhibitors
Michael S. Malamas et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis
Giuseppe Di Fede et al.
SCIENCE (2009)
A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase
Mesens Natalie et al.
TOXICOLOGY IN VITRO (2009)
Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans
Vivek C. Abraham et al.
JOURNAL OF BIOMOLECULAR SCREENING (2008)
High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening
P. J. O'Brien et al.
ARCHIVES OF TOXICOLOGY (2006)
SFTG international collaborative study on in vitro micronucleus test - I. General conditions and overall conclusions of the study
Elisabeth Lorge et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2006)
Advanced chemical methods in melanin determination
K Wakamatsu et al.
PIGMENT CELL RESEARCH (2002)